Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196126 | 1.00 | NPC1 (0.57) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5709362 | 0.89 | NPC1 (0.67) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL2481230 | 0.89 | NPC1 (0.67) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL8162012 | 0.86 | NPC1 (0.61) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL3641034 | 0.82 | FFAR1 (0.56) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL3057455 | 0.82 | TACR1 (0.60) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL3641032 | 0.82 | FFAR1 (0.56) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL27745006 | 0.78 | MLYCD (0.47) | — | |
| SCHEMBL20193690 | 0.77 | RAB9A (0.52) | NPC1RAB9AMAPTLMNASMN1; SMN2 | |
| SCHEMBL4530460 | 0.77 | NPC1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244617-B1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO MCNEIL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040092505-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | COATS STEVEN J (US) | 2004-05-13 | — | — | US | disclosed |
| US-6583179-B2 | For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1244617-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001047875-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | FSHR, GNRHR, SHBG | NPC1 4245/4885RAB9A 4358/4885MAPT 3084/4885 |
| US-20040092505-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | FSHR, GNRHR, SHBG | NPC1 4245/4885RAB9A 4358/4885MAPT 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.